Prospective, multicenter observational study, of the effectiveness of a standard of care protocol implemented to enhance home treatment of VTE. Study population will be selected as part of usual care as eligible for home treatment. Study personnel will travel to participating institutions to qualify the sites, deliver a Powerpoint® lecture to introduce the protocol, meet and train site principal investigators, emergency physicians and research personnel on the implementation of the protocol as part of usual clinical care, and data collection methods for a quality assurance registry with plans to use the data collected in this registry in future publications. Follow-up will be 30 days using medical records and/or telephone interview to assess for primary outcomes of bleeding or VTE recurrence.
Study Type
OBSERVATIONAL
Enrollment
1,300
Apixaban as standard of care for VTE
Rivaroxaban as standard of care for VTE
Eskenazi Health System
Indianapolis, Indiana, United States
Indiana University Health Methodist Hospital
Indianapolis, Indiana, United States
Number of re-hospitalization visits for VTE recurrence or bleeding
Re-hospitalization for \> 24 hours due to VTE recurrence or bleeding
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.